Save on Pertuzumab, Trastuzumab/Hyaluronidase-ZZXF with Coupons, Discounts & Savings Programs

Pertuzumab, Trastuzumab/Hyaluronidase-ZZXF is available as a single dose vial containing one of the following:

• 1,200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase/15 mL (80 mg, 40 mg, and 2,000 units/mL)
• 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase/10 mL (60 mg, 60 mg, and 2,000 units/mL)

Pertuzumab, Trastuzumab/Hyaluronidase-ZZXF is a combination medication used to treat HER2-positive breast cancers, together with other chemotherapy.

Pertuzumab, Trastuzumab/Hyaluronidase-ZZXF is a combination of three medications. Pertuzumab and trastuzumab are monoclonal antibodies that act as a human epidermal growth factor receptor 2 (HER2) inhibitor. It blocks a specific protein in the body that’s important for cell growth called HER2. HER2 is found on both normal and cancer cells. Cancer cells usually have more HER2 proteins than normal cells. This can cause cancer cells to grow more quickly than normal cells. When HER2 is blocked by Pertuzumab, Trastuzumab/Hyaluronidase-ZZXF, cancer cells can’t grow and spread as well.
Hyaluronidase is a protein that helps your body absorb pertuzumab and trastuzumab better when injected under the skin.

Pertuzumab, Trastuzumab/Hyaluronidase-ZZXF is given by a healthcare provider as an injection under the skin on the thigh. After the first dose, it’s given once every 3 weeks.

• For the first dose, you’ll get 1,200 mg of pertuzumab, 600 mg of trastuzumab, and 30,000 units of hyaluronidase
• For all other doses, you’ll get 600 mg of pertuzumab, 600 mg of trastuzumab, and 20,000 units of hyaluronidase

Pertuzumab, Trastuzumab/Hyaluronidase-ZZXF is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you. You should not use this medication if you have a known hypersensitivity to
pertuzumab, or trastuzumab, or hyaluronidase, or to any of its excipients.

Common side effects of Pertuzumab, Trastuzumab/Hyaluronidase-ZZXF:

• Hair loss
• Nausea
• Diarrhea
• Physical weakness
• Tiredness
• Mouth sores or inflammation
• Joint or muscle pain
• Constipation
• Vomiting

Serious side effects are rare with Pertuzumab, Trastuzumab/Hyaluronidase-ZZXF. Contact your healthcare provider immediately if you experience any of the following.

• Heart problems: chest pain, racing heartbeat, shortness of breath that usually worsens with activity or while lying flat, swelling of your legs or feet, sudden weight gain, fatigue
• Serious allergic reactions: trouble breathing, itching or hives, flushing, swelling, chest pain, fast heartbeat, dizziness
• Lung problems: shortness of breath, trouble breathing
• Serious infections (when receiving together with chemotherapy): repeated fevers, chills, sweating, cough, trouble breathing, severe diarrhea, vomiting, painful or frequent urination

The following medications may interact with Pertuzumab, Trastuzumab/Hyaluronidase-ZZXF:

• Patients who receive anthracycline after stopping Pertuzumab, Trastuzumab/Hyaluronidase-ZZXF may be at increased risk of cardiac dysfunction because of Pertuzumab, Trastuzumab/Hyaluronidase-ZZXF’s long washout period. If possible, avoid anthracycline-based therapy for up to 7 months after stopping Pertuzumab, Trastuzumab/Hyaluronidase-ZZXF. If anthracyclines are used, carefully monitor the patient’s cardiac function

Various FDA-approved generic manufacturers

Pertuzumab, Trastuzumab/Hyaluronidase-ZZXF can cause harm to your unborn baby when administered during pregnancy. You should take a pregnancy test prior to the initiation of Pertuzumab, Trastuzumab/Hyaluronidase-ZZXF. Females of reproductive potential to use effective contraception during treatment and for
7 months following the last dose of Pertuzumab, Trastuzumab/Hyaluronidase-ZZXF.

• Phesgo